BR112018009738A2 - biomarcadores para tratamento contra o câncer com apilimod - Google Patents

biomarcadores para tratamento contra o câncer com apilimod

Info

Publication number
BR112018009738A2
BR112018009738A2 BR112018009738A BR112018009738A BR112018009738A2 BR 112018009738 A2 BR112018009738 A2 BR 112018009738A2 BR 112018009738 A BR112018009738 A BR 112018009738A BR 112018009738 A BR112018009738 A BR 112018009738A BR 112018009738 A2 BR112018009738 A2 BR 112018009738A2
Authority
BR
Brazil
Prior art keywords
apilimod
biomarkers
cancer treatment
methods
compositions
Prior art date
Application number
BR112018009738A
Other languages
English (en)
Inventor
Conrad Chris
Lichenstein Henri
M Rothberg Jonathan
HERNANDEZ Marylens
BEEHARRY Neil
Beckett Paul
LANDRETTE Sean
Gayle Sophia
Xu Tian
Original Assignee
Lam Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lam Therapeutics Inc filed Critical Lam Therapeutics Inc
Publication of BR112018009738A2 publication Critical patent/BR112018009738A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente descrição refere-se a composições e métodos para tratamento contra o câncer em um indivíduo que tem células cancerígenas que superexpressam um fator de transcrição de microftalmia (mit) com apilimod e composições e métodos relacionados.
BR112018009738A 2016-01-21 2017-01-20 biomarcadores para tratamento contra o câncer com apilimod BR112018009738A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662281341P 2016-01-21 2016-01-21
PCT/US2017/014308 WO2017127661A1 (en) 2016-01-21 2017-01-20 Biomarkers for treating cancer with apilimod

Publications (1)

Publication Number Publication Date
BR112018009738A2 true BR112018009738A2 (pt) 2018-12-04

Family

ID=57963483

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018009738A BR112018009738A2 (pt) 2016-01-21 2017-01-20 biomarcadores para tratamento contra o câncer com apilimod

Country Status (13)

Country Link
US (1) US20190015421A1 (pt)
EP (1) EP3405199A1 (pt)
JP (1) JP2019502707A (pt)
KR (1) KR20180102559A (pt)
CN (1) CN108495633A (pt)
AU (1) AU2017210324A1 (pt)
BR (1) BR112018009738A2 (pt)
CA (1) CA3004636A1 (pt)
IL (1) IL259661A (pt)
MX (1) MX2018008964A (pt)
RU (1) RU2018130070A (pt)
TW (1) TW201726142A (pt)
WO (1) WO2017127661A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3861347B1 (en) * 2018-10-05 2022-12-21 Eisai R&D Management Co., Ltd. Biomarkers for a combination therapy comprising lenvatinib and everolimus
CN110496128B (zh) * 2019-09-23 2022-09-30 吉林大学 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US10179135B2 (en) * 2014-01-24 2019-01-15 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
JP2017524371A (ja) * 2014-05-23 2017-08-31 ジェネンテック， インコーポレイテッド Ｍｉｔバイオマーカーとその使用方法
JP6716585B2 (ja) * 2014-11-07 2020-07-01 エイアイ・セラピューティクス・インコーポレーテッド 結腸直腸癌の処置に使用するためのアピリモド
RU2727802C2 (ru) * 2014-11-07 2020-07-24 ЭйАй ТЕРАПЬЮТИКС, ИНК. Апилимод для применения в лечении рака почек
WO2016160102A1 (en) * 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Also Published As

Publication number Publication date
WO2017127661A1 (en) 2017-07-27
CA3004636A1 (en) 2017-07-27
EP3405199A1 (en) 2018-11-28
RU2018130070A (ru) 2020-02-21
AU2017210324A1 (en) 2018-08-16
MX2018008964A (es) 2018-11-09
IL259661A (en) 2018-07-31
US20190015421A1 (en) 2019-01-17
TW201726142A (zh) 2017-08-01
KR20180102559A (ko) 2018-09-17
CN108495633A (zh) 2018-09-04
JP2019502707A (ja) 2019-01-31

Similar Documents

Publication Publication Date Title
CO2020015255A2 (es) Métodos y composiciones para tratar el cáncer
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
CO2017010618A2 (es) Anticuerpos contra icos
BR112019011138A2 (pt) composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
BR112017020893A2 (pt) método para o tratamento de câncer
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
BR112018008503A2 (pt) método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer
BR112017011792A2 (pt) antena de abertura apoiada em uma cavidade
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
CO2017008129A2 (es) Método para prevenir o tratar la pérdida de la audición
BR112017009265A2 (pt) apilimode para uso no tratamento do câncer colorretal
BR112018013269A2 (pt) composições e métodos para a avaliação do risco de ocorrência do câncer
BR112018068027A2 (pt) método para tratar câncer em um paciente e composição farmacêutica
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
EP3531830A4 (en) METHODS AND COMPOSITIONS FOR IDENTIFICATION AND TREATMENT OF PATIENTS WITH SMALL CELL LUNG CANCER
BR112018009738A2 (pt) biomarcadores para tratamento contra o câncer com apilimod
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]